Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02096510
Other study ID # 2013/1738
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date March 27, 2014
Est. completion date December 2017

Study information

Verified date June 2024
Source Haukeland University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to compare the effects of tablet treatment, circadian and combined circadian and ultradian subcutaneous hydrocortisone infusion on steroid metabolism and tissue responses to therapy.


Description:

The conventional glucocorticoid replacement therapy in primary adrenal insufficiency (Addison's disease) and congenital adrenal hyperplasia renders the cortisol levels unphysiological, which may cause symptoms and long-term complications. This therapeutical approach does not enable to restore physiological circadian and ultradian rhythm of glucocorticoids. Current studies conclude that constant or unphysiological administration of glucocorticoids leads to abnormal gene transcription and causes sides effect of glucocorticoids treatment and long standing complications Glucocorticoid replacement is technically feasible by continuous subcutaneous hydrocortisone infusion, which can mimic not only the normal diurnal cortisol rhythm, but potentially also the ultradian cadence. This is a pilot trial with an open cross-over design of 3 x minimum 2 weeks in 10 patients comparing the effects of tablet treatment versus continuous subcutaneous hydrocortisone infusion versus ultradian subcutaneous hydrocortisone infusion on serum, salivary, tissue hormonal response and glucocorticoid related gene expression.


Recruitment information / eligibility

Status Completed
Enrollment 8
Est. completion date December 2017
Est. primary completion date December 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. clinical diagnosis of primary adrenal insufficiency 2. Written informed consent Exclusion Criteria:. 1. Diabetes mellitus 2. Severe cardiovascular disease 3. Active malignant disease 4. Pregnancy or breast feeding 5. treatment with interfering drugs 6. Intake of grapefruit juice

Study Design


Intervention

Drug:
Solu-Cortef
administration by pump for minimum 2 weeks
Cortef
tablet treatment 2 ro 3 times per day for 14 days

Locations

Country Name City State
Norway University Hospital Helse Bergen Bergen

Sponsors (1)

Lead Sponsor Collaborator
Haukeland University Hospital

Country where clinical trial is conducted

Norway, 

References & Publications (4)

Lightman SL, Conway-Campbell BL. The crucial role of pulsatile activity of the HPA axis for continuous dynamic equilibration. Nat Rev Neurosci. 2010 Oct;11(10):710-8. doi: 10.1038/nrn2914. Epub 2010 Sep 15. — View Citation

Lightman SL, Windle RJ, Julian MD, Harbuz MS, Shanks N, Wood SA, Kershaw YM, Ingram CD. Significance of pulsatility in the HPA axis. Novartis Found Symp. 2000;227:244-57; discussion 257-60. doi: 10.1002/0470870796.ch14. — View Citation

Lovas K, Husebye ES. Continuous subcutaneous hydrocortisone infusion in Addison's disease. Eur J Endocrinol. 2007 Jul;157(1):109-12. doi: 10.1530/EJE-07-0052. Erratum In: Eur J Endocrinol. 2008 Jun;158(6):939. Dosage error in article text. — View Citation

Simunkova K, Lovas K, Methlie P, Jovanovic N, Bifulco E, Bronstad I, Lightman SL, Husebye ES, Oksnes M. Pulsatile Subcutaneous Hydrocortisone Replacement in Primary Adrenal Insufficiency. Horm Metab Res. 2023 Jul;55(7):471-478. doi: 10.1055/a-2092-5228. E — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Serum cortisol -24 hours curve admission to hospital for 24 hours 24 hours
Secondary Salivary cortisol - 24 hours curve admission to the hospital for 25 hours 24 hours
Secondary 24 h urine cortisol and metabolites urine samples for 24 hours 24 hours
Secondary levels of corticotropic hormone blood samples 24 hours
Secondary 24 hours curve of tissue cortisol The tissue effect of glucocorticoid replacement - 24 hours curve of tissue cortisol (microdialysis) 24 hours
Secondary gene expression m RNA expression of genes 24 hours
See also
  Status Clinical Trial Phase
Completed NCT02152553 - Biomarker(s) for Glucocorticoids N/A
Recruiting NCT03210545 - A Study of Markers of Glucocorticoid Effects in Patients With Addisons Disease (DOSCORT) Phase 4
Enrolling by invitation NCT04789993 - Additional Autoimmune Diseases With Type 1 Diabetes in Pediatrics at Diabetes Diagnosis and During Follow-up
Unknown status NCT01847690 - Effect of Cortisol on Physical Exertion in Patients With Primary Adrenal Failure Phase 2
Recruiting NCT04374721 - Clinical Study on Circadian Genes Dysregulation in Patients With Glucocorticoid Disorders N/A
Recruiting NCT01793168 - Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Completed NCT00251836 - Adrenal Function After Living Kidney Donation N/A
Completed NCT03941184 - Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity
Recruiting NCT05515055 - Does Relative Hypoglycaemia &/or Sleep Disturbance Contribute to the Lethargy Observed in Addison's Disease
Terminated NCT01840189 - Continuous Subcutaneous Hydrocortisone Infusion In Addison's Disease and Type 1 Diabetes Phase 2
Completed NCT01271296 - Effects and Interactions of Liquorice and Grapefruit on Glucocorticoid Replacement Therapy in Addison's Disease N/A